Convalescents vaccinated with Soberana Plus have highest amount of antibodies against the coronavirus in CubaConvalescents vaccinated with Soberana Plus have highest amount of antibodies against the coronavirus in Cuba

The principal investigator of the clinical trials, Arturo Chang, pointed out that as part of the studies, the levels of antibodies have been evaluated, which turned out to be higher than those of convalescent patients without vaccination compared to those who received two doses of Soberana 02 plus the booster dose of Soberana Plus.

by  OnCuba StaffJune 1, 2021in Coronavirus, Science in Cuba

About to conclude the inoculation of the volunteers of phase II clinical trial with the Cuban Soberana Plus vaccine candidate, its developers affirm that the convalescents from COVID-19 who received this drug are those with the most antibodies against the coronavirus in Cuba.

The principal investigator of the clinical trials, Arturo Chang, pointed out that as part of the studies, the levels of antibodies have been evaluated, which turned out to be higher than those of convalescent patients without vaccination compared to those who received two doses of Soberana 02 plus the booster dose of Soberana Plus, reported the Agencia Cubana de Noticias (ACN) news agency.

Cited by the agency, Chang clarified that these results were obtained in a previous Phase I trial based on the comparison of the antibodies developed by those inoculated with the injectable, created by the Finlay Vaccine Institute, in relation to those produced naturally when infected with SARS-CoV-2.

“Those people who recovered from the disease and were left with high antibody titers became part of the robust panel of Cuban convalescents, difficult to overcome, but after a dose of Soberana Plus in those who suffered from the virus — and were left with low antibody titers — it was possible to match and even exceed the panel,” explained the expert, who, however, did not offer figures to detail the comparison.

Likewise, the specialist stressed that the vaccine candidate has the potential to increase the immunity of convalescents with the application of a single dose, and assured that so far few adverse events have been registered “so it does not offer any risk to elderly people.”

By US-Cuba Normalization Committee

Organizing Committee, International and Nationwide Conference for the Normalization of US-Cuba Relations.

Comments are closed.